Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.
Furber M, Alcaraz L, Luckhurst C, Bahl A, Beaton H, Bowers K, Collington J, Denton R, Donald D, Kinchin E, MacDonald C, Rigby A, Riley R, Soars M, Springthorpe B, Webborn P. Furber M, et al. Among authors: bahl a. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7702-6. doi: 10.1016/j.bmcl.2012.09.113. Epub 2012 Oct 23. Bioorg Med Chem Lett. 2012. PMID: 23142617
Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E, Dovedi SJ, Murata M, Matsui H, Leishman AJ, Bell J, Ferguson D, Heaton SP, Oki T, Tomizawa H, Bahl A, Takaku H, Wilkinson RW, Harada H. Koga-Yamakawa E, et al. Among authors: bahl a. Int J Cancer. 2013 Feb 1;132(3):580-90. doi: 10.1002/ijc.27691. Epub 2012 Jul 11. Int J Cancer. 2013. PMID: 22733292
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
Bahl A, Barton P, Bowers K, Caffrey MV, Denton R, Gilmour P, Hawley S, Linannen T, Luckhurst CA, Mochel T, Perry MW, Riley RJ, Roe E, Springthorpe B, Stein L, Webborn P. Bahl A, et al. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6694-9. doi: 10.1016/j.bmcl.2012.08.103. Epub 2012 Sep 11. Bioorg Med Chem Lett. 2012. PMID: 23021991
The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bahl A, Barton P, Bowers K, Brough S, Evans R, Luckhurst CA, Mochel T, Perry MW, Rigby A, Riley RJ, Sanganee H, Sisson A, Springthorpe B. Bahl A, et al. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6688-93. doi: 10.1016/j.bmcl.2012.08.124. Epub 2012 Sep 15. Bioorg Med Chem Lett. 2012. PMID: 23031591
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.
Furber M, Alcaraz L, Luckhurst C, Bahl A, Beaton H, Bowers K, Collington J, Denton R, Donald D, Kinchin E, MacDonald C, Rigby A, Riley R, Soars M, Springthorpe B, Webborn P. Furber M, et al. Among authors: bahl a. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7707-10. doi: 10.1016/j.bmcl.2012.09.112. Epub 2012 Oct 10. Bioorg Med Chem Lett. 2012. PMID: 23116889
610 results